Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
143G03-PNU-159682 ADC
- Development stage
- Preclinical
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
143G03-PNU-159682 ADC is an experimental antibody-drug conjugate (ADC) designed to target the L1 cell adhesion molecule (L1CAM), a transmembrane protein highly expressed on metastasis stem cells (MetSCs) across various solid tumors. The ADC is composed of the monoclonal antibody 143G03, which exhibits high affinity and specificity for the extracellular domain of human L1CAM, conjugated to the extremely potent anthracycline derivative PNU-159682. PNU-159682 is a metabolite of nemorubicin that acts as a powerful DNA intercalator and cytotoxic agent. By specifically targeting L1CAM, the ADC aims to eliminate drug-resistant cell populations responsible for metastatic growth and cancer relapse. Preclinical studies have demonstrated significant efficacy in mouse models of triple-negative breast cancer and lung adenocarcinoma, showing robust tumor control and improved survival rates.
- Other names
- L1CAM-targeting ADCL-1CAM-targeting ADCL 1CAM-targeting ADC143G03-PNU-159682
02
Targets
TOP2A (DNA topoisomerase II)L1CAMDNA
Beyond the preview
Go deeper on 143G03-PNU-159682 ADC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 143G03-PNU-159682 ADC.